Incident colorectal cancer in Lynch syndrome is usually not preceded by compromised quality of colonoscopy by Lappalainen, Jutta et al.
1
Incident colorectal cancer in Lynch syndrome is usually not preceded by compromised quality
of colonoscopy
Jutta Lappalainen1*, Darja Holmström2*, Anna Lepistö3,4, Juha Saarnio5, Jukka-Pekka Mecklin6,7,
Toni Seppälä3,8
1University of Oulu, School of Medicine, Oulu, Finland
2University of Helsinki, Medical School, Helsinki, Finland
3Department of Abdominal Surgery, Helsinki University Central Hospital, Helsinki, Finland
4Research program in applied tumor genomics, University of Helsinki, Helsinki, Finland
5Department of Surgery, Oulu University Hospital, Oulu, Finland
6Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland
7Faculty of Sports and Health Sciences, University of Jyväskylä, Jyväskylä, Finland
8Department of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA




Dept. of Surgical Oncology














Lifetime incidence of colorectal cancer (CRC) especially in carriers of MLH1 and MSH2
pathogenic germline variants in mismatch repair genes is high despite ongoing colonoscopy
surveillance. Lynch syndrome (LS) registries have been criticized for not reporting colonoscopy
quality adequately.
Methods
Prospective follow-up data from the national registry were combined with a retrospective
assessment of the colonoscopy reports from Helsinki University Hospital electronic patients
records in 2004–2019.
Results
Total of 366 MLH1, MSH2 and MSH6 carriers underwent 1564 colorectal endoscopies (mean 4.3
per patient, range 1–10) at a single unit. At least one subsequent examination was performed
on 336 patients.
Bowel preparation was suboptimal (Boston Bowel Preparation Scale 0–2) on either right or left
side of the colon in 12.9% of planned surveillance examinations. Caecal intubation rate for full-
length colonoscopies was 98.9%. Adenoma detection rate (ADR) was 15.8% in 2004–2014 but
substantially increased (21.9%) after introduction of high-definition (HD) technology in 2015–
2019 (p=0.004; 18.7% across all examinations).
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CRCs were detected in 23 cases. Nineteen cancers were detected after 977 optimal quality
colonoscopies and 4 after 151 compromised quality (BBPS <3 or non-complete examination;
p=0.16). Advanced neoplasias were not more frequently reported after compromised quality
examinations.
Conclusion
The majority of LS-associated incident CRCs were detected after colonoscopies with proper
bowel preparation and complete examination. There is a considerable time trend towards
higher ADR after introducing HD technology of endoscopes. The effect of time trend in ADR to
CRC incidence in LS needs to be studied in larger, prospective settings.
KEYWORDS: Lynch Syndrome, hereditary non-polyposis colorectal cancer, surveillance
colonoscopy, colonoscopy, colorectal cancer
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Introduction
Incident colorectal cancer (CRC) of a pathogenic mismatch repair variant carrier (path_MMR) at
a planned surveillance colonoscopy is not a rare event. Recent large prospective studies have
shown that up to 50% of path_MLH1 and path_MSH2 carriers develop a CRC during their
lifelong 1-3-yearly screening that was previously thought to prevent the Lynch syndrome (LS)
associated CRCs by meticulous adenomectomies [1-4]. The findings indicate that the
effectiveness of colonoscopy in clinical practice is lower than was interpreted from early clinical
intervention studies [5] [6]. The following discussion has raised questions of the historical
quality of colonoscopy as a factor contributing to poor preventive performance [7]. On the
other hand, alternative hypotheses based on different tumor biology have been proposed:
some LS-associated CRCs arise directly from mismatch repair deficient crypt foci and may not
be preceded by a macroscopically distinct precursor adenoma [8, 9].
There may be multiple reasons why colonoscopy with polypectomy fails to prevent CRC after
certain extent. One possible explanation may be that the quality of colonoscopy measured by
the key performance indicators (KPI) of endoscopic quality are compromised, which leads to
missed precursor lesions and subsequently to increased incidence of CRC. Since CRC incidence,
survival and stage have been consistently shown not to correlate with the interval between
surveillance colonoscopies in two large prospective databases [1, 2, 10-12], we sought to
investigate whether success in bowel preparation, caecal intubation rate or adenoma detection
rate would explain the LS-associated CRC incidence during the past 15 years in the highest




Lynch Syndrome Registry of Finland (LSRFi) prospectively records the cancer diagnoses, planned
and performed endoscopic procedures and their histological findings. Surveillance
colonoscopies of about 1500 identified path_MMR carriers are provided in public healthcare
mostly by 5 university hospitals and 7 other major hospitals. The Helsinki University Central
Hospital (HUCH) is the largest single center performing surveillance colonoscopies of high-risk
individuals. Confirmed path_MMR carriers under surveillance in HUCH were listed from LSRFi
and the quality indicators of their colonoscopy surveillance were reviewed from the HUCH
electronic patient records in 2004–2019. Only colonoscopies during this study period were
assessed for quality, without selection. Patients deceased during study period were included.
Colonoscopy findings were reviewed against LSRFi data to confirm that no CRC diagnoses were
missed. LSRFi data is in turn periodically compared to data of the Finnish Cancer Registry to
confirm that inadequate recording or reporting does not lead to loss of follow-up.
Surveillance colonoscopies
Endoscopic surveillance by rectosigmoideoscopies and colonoscopies (later referred to as
colonoscopies or endoscopies) were performed solely by experienced specialists working as
attendings/consultants of the colorectal surgery unit of the HUCH. The mean number of full-
length surveillance colonoscopies per observer per year was 122. Altogether, the observers
performed 250-300 lower gastrointestinal endoscopies yearly per person.
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In 2004-2007, endoscopy equipment contained Olympus CF Q 145 L, 160 DL and 165 L. From
2008 to 2014, the Pentax EC 3890 Li and Olympus CF Q 160 DL, CF H 180 DL and H 180 AL were
primarily used. From January 1st, 2015 onwards, the colonoscopes have been Olympus CF H 180
AL, HQ 190, HQ 190 L, and HQ 190 DL series white light endoscope with high definition (HD)
image and narrow band imaging (NBI) option (supplementary table 1). Either CO2 or room air
insufflator were used. Magnetic 3D endoscope location device (ScopeGuide UPD, Olympus) was
used when available (2014 onwards) and compatible with the endoscope model in use.
Chromoendoscopy was not routinely performed during the study period.
Bowel preparation was advised by written instructions that were sent to patients with their
appointment confirmation. Either Phosphoral (until 2014; sodiumdihydrophosphate, di-
sodiumphosphate-decahydrate; CCS Healthcare, Zaragoza, Spain), MoviPrep (PEG-3350, sodium
sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral
solution; Salix Pharmaceuticals, USA) or ColonSteril (macrogol 4000, sodium chloride,
potassium chloride, sodium sulfate, sodiumbicarbonate; Orion Ltd, Finland) were
recommended, in written form and again orally at the pharmacy, to use according the
manufacturer’s protocol for bowel preparation before endoscopy.
Colonoscopies were scheduled mainly three-yearly for path_MMR carriers without previous
CRC and 2-yearly for those with a previous CRC. Shorter colonoscopy intervals (6 to 12 months)
were scheduled for postoperative surveillance after surgically treated CRC, or verifying the
result of an endoscopic removal of a neoplastic lesion.
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Review of colonoscopy quality
Endoscopy reports were reviewed for colonoscopy quality using a Boston Bowel Preparation
Scale (BBPS) simplified for this study as follows. The modification included that only right
(proximal or oral from ceacum to splenic flexure) and left (from splenic flexure to anus) side
were assessed separately and the quality of the final visibility to bowel mucosa after
endoscopic rinsing was graded by a numerical value 0, 1, 2 or 3. The quality of the bowel
preparation was assessed verbally and images by the physician performing the procedure and
translated into modified BBPS by the reviewers (DH and JL) gathering the data. For adenoma
detection rate (ADR), determined as a finding containing either adenoma, serrated adenoma or
colorectal cancer as verified by a report from histopathological examination, number of
endoscopies with an event was divided by number of examinations excluding postoperative
controls (when entire large bowel length was not necessarily assessed).
Statistics
Retrospective evaluation data were collected in Excel (Microsoft, USA) together with
prospective LSRFi data and analysed in SPSS 25.0 (IBM, USA). Chi-square test was used for
determining statistical difference between variables.
Ethical considerations
Institutional research permission was obtained from the Helsinki University Hospital. As this
was a study based on patient records, separate ethical board review was not required.
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RESULTS
During the 15-year study period in 2004–2019, 366 path_MMR carriers underwent 1564 (mean
4.3 per patient, range 1–10) colorectal endoscopy examinations at the HUCH endoscopy unit.
For 30 carriers (8.2%), the colonoscopy was their only one during the study period, mainly due
to recent onset of the surveillance program. Inclusion criteria for the study to assess the effect
of the quality of the previous colonoscopy to the finding at the subsequent colonoscopy was
therefore fulfilled for 336 carriers that underwent 1534 examinations. Mean follow-up was 9.1
years. Table 1 presents the demographic information of the 336 carriers fulfilling the inclusion
criteria.
Overall quality of colonoscopies
Table 2 presents the basic characteristics of the 1534 endoscopies during surveillance with their
indications and main findings. Out of 1534 examinations, 1383 endoscopies (90.2%) were
planned primary surveillance examinations with an intention to view the entire large bowel
length, while the rest were either postoperative control examinations that were based on
symptoms, or early repeat procedures due to failure of previous attempt. Out of 1383, the
entire large bowel length was examined successfully in 1361 cases (98.4%). Out of 1383, 1046
were planned and scheduled full-length colonoscopies for patients with no prior colorectal
surgery, in 1035 of which caecum was reached (caecal intubation rate 98.9%).
9
ADR over 1464 examinations (excluding only postoperative controls) was 18.7%. Advanced
(including serrated) adenomas were found in 5.1% across all (n=1464) examinations. There was
a considerable time trend for better ADR per examination from 2004–2014 towards 2015–2019
after HD-able colonoscopes were introduced: 15.8% versus 21.9 %, (p=0.004, Pearson’s chi-
square). Unsuccessful colonoscopies were rare, but reported slightly more frequently during
2015–2019 compared to 2004–2014.
Examinations were performed within 37 months from previous colonoscopy in 89.7% of the
times. At the inclusion round (first colonoscopy during study period 2004-2019), 10 CRCs were
detected. Since these ten were not preceded by an examination during the study period, the
quality of the previous colonoscopies were not evaluated.
Quality of previous colonoscopies related to subsequent cancer finding
At their second colonoscopy recorded to the LSRFi during 2004-2019, 250 carriers (74.4%) had
not undergone colorectal surgery and 86 (25.6%) had had previous large bowel resections.
During subsequent surveillance colonoscopies after the inclusion round, 24 CRCs in 23 patients
were diagnosed (one patient with two synchronous cancers; table 3). Nineteen patients were
diagnosed with CRC after 977 optimal quality colonoscopies and four after 151 compromised
quality colonoscopies (BBPS < 3 or non-complete examination; p=0.16). Adenoma was removed
from the same bowel segment in 2/23 at the previous colonoscopy. Two follow-up
colonoscopies with a cancer finding clearly exceeded their scheduled interval (41 and 48
10
months). One cancer in the transverse colon was diagnosed due to symptoms 7 months after
previous examination, where no signs of compromised quality were recorded. In examinations
that were preceded by a (quality-assessed) previous endoscopy, 42 advanced neoplasias were
detected in 2015–2019 in 470 colonoscopies and 37 advanced neoplasias in 2004–2014 in 658
colonoscopies (p=0.032).
Other findings at the subsequent colonoscopy were not significantly associated with previous
colonoscopy quality. With intention to examine the entire remaining large bowel, 1128
surveillance colonoscopies showed no difference in the frequency of advanced or non-
advanced lesions between those with previously well-performed colonoscopy and those
preceding a compromised quality procedure (table 4). In a sensitivity analysis, those with only




The current report indicates that the vast majority of incident colorectal cancers that occur
during surveillance for pathogenic mismatch repair variants causing Lynch syndrome are not
preceded by poor colonoscopy quality that would result from incomplete examination or
inadequate bowel cleansing. There was a considerable time trend towards better ADR at the
end of the study period, likely reflecting the technological evolution of endoscopes.
It has been generally accepted for over 20 years that the core of the CRC prevention and early
diagnosis in LS is formed by the regular endoscopic surveillance by colonoscopies that decrease
the mortality and the incidence of CRC compared to no surveillance [5] [6]. However, 15% of
path_MMR still continued to develop CRC within 10 years during surveillance [6, 13] [14], that
has been confirmed by large registry studies [1, 2]. Colonoscopy was widely adopted in clinical
guidelines and even very short (annual) intervals between examinations are still being
recommended [15-17]. However, it has been recently shown in large prospective datasets that
the shorter intervals between colonoscopies do not benefit the patients compared to 3-yearly
intervals in terms of decreased CRC incidence, better overall survival or lower AJCC stage of the
CRC [1, 2, 10, 12]. On the other hand, the excellent survival after CRC reported in the same
studies proves that the role of colonoscopy is justified and can be considered as success in
terms of preventing cancer deaths compared to no surveillance [12]. The lack of benefit from
very frequent colonoscopy compared to less frequent has raised questions and directed the
research towards finding the differences between genes and carcinogenetic pathways. The
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quality of colonoscopy surveillance has been questioned as one reason for incident and interval
cancers since it has not been widely reported to prospective international databases.
We hypothesized that if the quality of colonoscopy was the reason for high incidence during
colonoscopy surveillance, it should be clearly evident in the setting where the longest intervals
between colonoscopies are being recommended, such as Finland with a 2–3-yearly
recommendation. As in some Nordic countries, the colonoscopies in the current study were
performed by dedicated colorectal surgeons. KPIs did not seem to be substantially
compromised, and the few shortcomings in the measured quality did not seem to cause the
majority of the cancers that were detected. The unlikeliness of compromised quality as a
causative factor in a setting with highest vulnerability of the surveillance program (longest
interval) makes it even less probable for the high (or even higher) CRC incidence to be caused
by poor quality in the short interval programs. In fact, the point estimates for CRC incidence
have historically been lower in the 3-year interval groups than in 1–2 yearly interval groups [2,
10].
The optimal adenoma detection rate during colonoscopy surveillance of path_MMR carriers is
not known, and may be largely dependent on age, the genetic distribution of the pathogenic
variants in the study cohort, the extent of previous large bowel resections, as well as
geographical and ethnic variability in the adenoma risk. In the current study, the 22% ADR of a
single center is higher than previously reported mean 16% in the database study of Finland,
Germany and Netherlands [2], but lower than 23-30% reported by recent trial series in
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specialized centers in Europe [18-22]. The differences are unlikely to be caused by inter-
observer differences only, although the technology may play a role. It is possible that the
endoscopies performed with more advanced technology, such as HD video quality, have
increased the ADR in the more recent studies, in addition to trial setting where colonoscopy is
performed twice in back-to-back manner. The unique cascade testing performance and
inclusion to surveillance in Finnish LS registry during the past 35 years separates Finland from
more recently established registries. Since the high-risk families are carefully scrutinized and
the uptake to genetic testing is high, many more young individuals are under surveillance than
in settings where surveillance is performed to mostly older probands. This decreases the ADR
since adenoma incidence is heavily dependent on age.
We also report a time trend towards higher ADR in 2015–2019 when HD-level colonoscopes
became widely in use in our institution. In addition to HD techniques, at least
chromoendoscopy (CE) may be more efficient in detecting lesions on the ascending side of the
colon based on recent meta-analysis [23], although CE did not overall result in higher ADR in
high-volume LS surveillance centers compared to HD WLE [20]. Furthermore, a recent back-to-
back trial demonstrated that indigo carmine CE outperforms third generation NBI colonoscopy
in ADR (20% versus 30%) and that the rate of missed adenomas is high even with modern NBI
[21].
Especially for proximal colon adenomas and flat lesions, the miss rates in studies carried out by
tandem colonoscopies have been high. Based on a recent meta-analysis, up to 26% of
14
adenomas in general, 9% of advanced adenomas, 14% of right-sided adenomas, 27% of
serrated polyps and 34% of flat adenomas are missed during colonoscopies [24]. Adenoma miss
rate was especially high (33%) in patients with high risk of CRC [24]. On the other hand, as many
of these studies reporting high ADRs have been tandem studies, CE with substantially longer
withdrawal times being the latter and preceded by WLE of the two, which may have accounted
for the higher detection rate [7].
ADR is a widely used endpoint in the endoscopic literature, as it has been assumed that all
adenocarcinomas have always been preceded by an endoscopically removable precursor. On
the other hand, it still remains to been proven if more advanced technologies or the recent high
ADR performance as a result of HD image, NBI and CE – possibly outperforming the
conventional WLE techniques – would actually convert to decreased CRC incidence in the LS
setting.
Furthermore, recent advances in the study of carcinogenetic pathways in LS suggest that all
adenocarcinomas are not developing through traditional adenoma-carcinoma sequence but
may start directly from the MMR-deficient crypt foci, without preceding adenoma phase [8, 9].
Therefore, until further studies show CRC incidence, survival or cost benefit from high ADR
using the latest endoscopic techniques, adequate ADR remains an open question. In fact, the
high numbers of CRCs found during surveillance and lack of association between the
colonoscopy interval and stage, survival and incidence may be accounted for by over-diagnosis
[11]. The current finding that more advanced lesions were found in conjunction with increasing
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ADR after moving to era of HD image would support this idea. The increasing number of
findings could alternatively be interpreted as an example of lead-time bias associated with
improved performance of a diagnostic modality.
The strengths of this study are the population-based patient material, prospective registry data
verifying the findings and robust inclusion criteria that enabled assessing only colonoscopies
that were preceded by at least one other colonoscopy during the study period. The weaknesses
of the study were the retrospective nature of the bowel preparation quality assessment and
unavailability of the colonoscopy withdrawal time. As in all studies other than tandem
colonoscopy studies, the miss rates of adenomas could not be assessed in the current analysis.
It is possible that the somewhat limited ADR compared to recently reported very high ADRs
may be resulting from missed small or flat adenomas, especially due to delay in the widespread
use of HD technology.
The high quality colonoscopy surveillance remains the cornerstone of the risk-reducing
surveillance in LS. Compromised colonoscopy quality seems infrequent and the results of the
current study do not support the hypothesis that colonoscopy quality is the only major cause of
the incident/interval colorectal cancers during LS endoscopic surveillance in this population. For
patients and healthcare, it is pivotal to understand that incident colorectal cancers during
planned endoscopy surveillance program do not reflect solely unsuccessful performance or
malpractice, but may rather be a hallmark of the underlying variation of the cancer biology that
so far has not been solved by current endoscopic techniques. Population-specific ADRs should
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be studied systematically and the target thresholds for detection to be set for centers
performing surveillance for high-risk individuals. The time trends in colonoscopy should be
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Figure legends
Figure 1. Formation of the study cohort.
Table legends
Table 1. Demographic characteristics of the study population and surveillance examinations
Table 2. Indications, findings and performance during colonoscopy surveillance, presented by
previous colorectal surgery status and era of colonoscopies
Table 3. Colorectal cancers found at the second and following surveillance colonoscopies during
the study period (2004-2019). Quality and the findings of the previous colonoscopies are
presented for each cancer.
Table 4. Findings at the next examination after surveillance colonoscopies with optimal and
compromised bowel preparation and/or completion
Table 5. Colorectal cancer and advanced adenoma findings at the next examination after
optimal or compromised quality of colonoscopy presented by previous colorectal surgery status





No previous surgery Total
N 76 (22.6%) 260 (73.4) 336 (100%)
Age at baseline (mean) 54 40 43
Sex Male 39 (51.3%) 136 (52.3%) 175 (52.1%)
Female 37 (48.7%) 124 (47.7%) 161 (47.9%)
Gene MLH1 56 (73.7%) 184 (70.8%) 240 (71.4%)
MSH2 13 (17.1%) 49 (18.8%) 62 (18.5%)
MSH6 7 (9.2%) 27 (10.4%) 34 (10.1%)
Previous cancer Yes 72 (94.7%) 1 (0.4%) 73 (21.7%)
No 4 (5.3%) 259 (99.6%) 263 (78.3%)
Mean number of colonoscopies  4.9  4.5  4.6
Mean follow-up time  8.1  9.1  8.9
Total number of colonoscopies 407 (26.5%) 1127 (73.5%) 1534 (100%)
Total number of follow-up years 617 (20.6%) 2372 (79.4%) 2989 (100%)
2
Table 2
Whole bowel left Partial colectomybefore baseline p 2004–2014 2015–2019 p
Total
cohort
N of patients 260 76 NA NA 336
Number of examinations 1127 (73.5%) 407 (26.5%) 1109 (65.8%) 525 (34.2%) 1534
Mean time interval, years (SD) 2.78 (0.85) 1.91 (1.01) < 0.001 NA NA 2.54
Era Examination 2004-2014 754 (74.7%) 255 (25.3%)
0.121
1109 (100%) 0 (0%)
NA
1009
Examination 2015-2019 373 (71.0%) 152 (29.0%) 0 (0%) 525 (100%) 525
Reason Planned surveillanceexamination 1046 (92.8%) 337 (82.8%)
< 0.001
930 (83.9%) 453 (86.3%)
0.003
1383
Unplanned due to symptoms 45 (4.0%) 21 (5.2%) 33 (29.8%) 33 (6.3%) 66
Early repeat due to previous
quality issues 7 (0.6%) 8 (2.0%) 7 (0.6%) 8 (1.5%) 15
Post-procedure control 29 (2.6%) 41 (10.1%) 39 (3.5%) 31 (5.9%) 70
Primary finding Colorectal cancer* 23 (2.0%) 10 (2.5%)
0.067
20 (1.8%) 13 (2.5%)
0.002
33
Colorectal cancer at first
colonoscopy during study
period**
9 1 8 2 10
Adenoma (tubular or
tubulovillous) with high grade
dysplasia or size > 1 cm
34 (3.0%) 23 (5.7%) 29 (2.6%) 28 (5.3%) 47
Serrated adenoma 16 (1.4%) 2 (0.5%) 9 (0.8%) 9 (1.7%) 18
Tubular adenoma with low
grade dysplasia 120 (10.6%) 46 (11.3%) 100 (9.0%) 66 (12.6%) 166
Hyperplastic polyp(s) 178 (15.8%) 47 (11.5%) 170 (15.3%) 55 (10.5%) 225
Other polyp(s) 6 (0.5%) 2 (0.5%) 8 (0.7%) 0 (0%) 8
Other finding 44 (3.9%) 20 (4.9%) 39 (3.5%) 25 (4.8%) 64
No biopsies or no diagnostic
findings 706 (62.6%) 257 (22.8%) 634 (57.2%) 329 (62.7%) 963
Adenoma detection rate (%) 17.0 20.2 0.168 15.8 21.9 0.004 18.7
Bowel preparation
quality mBBPS 3 (optimal) 904 (86.4%) 300 (89.0%) 0.217




mBBPS < 3 (compromised) 142 (13.6%) 37 (11.0%) 99 (10.6%) 80 (17.7%) 179(12.9%)
Completeness of Complete 1035 (98.9%) 326 (96.7%) 0.005 920 (98.9%) 441 (97.4%) 0.028 1361
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examination (98.4%)
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F MLH1 age 32,hemicol. l.dx.
Symptomat











Planned 26 2 2 Complete Hyperplasticpolyp
Right
hemicolon
9 27.0 36.5 Righthemicolon
Adenoca
T1N0M0 M MLH1 Planned 36 2 2 Complete No findings
10 43.6 50.5 Righthemicolon
Adenoca





11 34.4 43.5 Lefthemicolon
Adenoca





12 57.5 66.6 Righthemicolon
Adenoca







































16 37.3 46.4 Transversecolon
Adenoca


















18 61.4 70.6 Transversecolon
Adenoca





19 40.8 53.9 Lefthemicolon
Adenoca





20 37.6 54.9 Righthemicolon
Adenoca







21 57.1 65.5 Rectum AdenocaT1N0M0 F MSH2
age 55,











ic 17 N/A 3 Complete No findings












Following colonoscopy finding Previous colonoscopy quality
BBPS 3 and all large bowel
examined BBPS < 3 or all large bowel not examined
N 977 151 p
Colorectal cancer 19 (1.9%) 4 (2.6%)
0.163
Adenoma (tubular or tubulovillous) with
high grade dysplasia or size > 1 cm 34 (3.5%) 6 (4.0%)
Serrated adenoma 14 (1.4%) 2 (1.3%)
Tubular adenoma with low grade
dysplasia 109 (11.2%) 29 (19.2%)
Hyperplastic polyp(s) 153 (15.7%) 20 (13.2%)
Other finding 56 (5.7%) 3 (2.0%)
No biopsies or no diagnostic findings 592 (60.6%) 87 (57.6%)
6
Table 5
All patients Patients with no prior colorectal surgery beforesecond colonoscopy during the study period
n=336 n=250
BBPS 3 and all large
bowel examined in
previous colonoscopy
BBPS < 3 or all large
bowel not examined in
previous colonoscopy
p
BBPS 3 and all large
bowel examined in
previous colonoscopy
BBPS < 3 or all large






67 (6.9%) 12 (7.9%)
0.625
47 (6.4%) 5 (4.6%)
0.455No finding or low risk
finding in current
colonoscopy
910 (93.1%) 139 (92.1%) 683 (93.6%) 104 (95.4%)
